Atreca Inc
NASDAQ:BCEL
Intrinsic Value
Atreca, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one
BCEL
stock under the Base Case scenario is
1.779
USD.
Compared to the current market price of 0.077 USD,
Atreca Inc
is
Undervalued by 96%.
Atreca Inc's market capitalization is 3m USD.
BCEL stock price is 0.077 USD.
BCEL stock price (0.077 USD) is 96% less than its Intrinsic Value (1.779 USD).
BCEL. Open Relative Valuation
BCEL.
BCEL has negative Free Cash Flow for the last twelve months.
BCEL's short-term assets (25m USD) exceed its short-term liabilties (16m USD).
BCEL has negative Operating Income for the last twelve months.
BCEL has negative Net Income for the last twelve months.
BCEL's long-term assets (26m USD) exceed its long-term liabilties (16m USD).
BCEL's ROE (Return on Equity) has significantly decreased in the last 3 years from -47% to -183%, and is approaching profitability.
BCEL's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -275% to -183%, and is approaching profitability.
BCEL's ROE (Return on Equity) for the past 12 months is negative and is equal to -183%.
BCEL's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -183%.
BCEL has negative three-year average ROE (Return on Equity): -73%. The company is not efficient at transforming stockholders' equity into net income.
BCEL has negative three-year average ROIC (Return on Invested Capital): -243%. The company is not efficient at using invested capital to generate operating income.
BCEL's D/E (Debt to Equity) is very low and is equal to 0.
BCEL's Altman Z-Score is very low and is equal to -38.39.
Fundamental Analysis
Atreca Inc
Balance Sheet Decomposition
Atreca Inc
| Current Assets | 24.7m |
| Cash & Short-Term Investments | 21.4m |
| Receivables | 500k |
| Other Current Assets | 2.8m |
| Non-Current Assets | 1.6m |
| PP&E | 1.6m |
| Current Liabilities | 15.6m |
| Accounts Payable | 4.1m |
| Accrued Liabilities | 10.6m |
| Other Current Liabilities | 900k |
Earnings Waterfall
Atreca Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-78.4m
USD
|
|
Operating Income
|
-78.4m
USD
|
|
Other Expenses
|
-19.4m
USD
|
|
Net Income
|
-97.8m
USD
|
Free Cash Flow Analysis
Atreca Inc
What is Free Cash Flow?
BCEL Profitability Score
Profitability Due Diligence
Atreca Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Atreca Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
BCEL Solvency Score
Solvency Due Diligence
Atreca Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Atreca Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BCEL Price Targets Summary
Atreca Inc
Ownership
BCEL Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BCEL Price
Atreca Inc
| Average Annual Return | -40.14% |
| Standard Deviation of Annual Returns | 42.72% |
| Max Drawdown | -100% |
| Market Capitalization | 3m USD |
| Shares Outstanding | 39 620 000 |
| Percentage of Shares Shorted | 1.02% |
Company Profile
Atreca Inc
Country
Industry
Market Cap
Dividend Yield
Description
Atreca, Inc. is a biopharmaceutical company. The company is headquartered in San Carlos, California and currently employs 134 full-time employees. The company went IPO on 2019-06-20. The firm use its platform to discover and develop antibody-based immunotherapeutic to treat a range of solid tumor types. The firm's lead product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. Its platform enables it to interrogate an active B cell response within an individual cancer patient to identify antibody-target pairs, which enable them to develop antibody-based product candidates to treat patients with solid tumors. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. APN-122597 is its other product candidate. The firm's Immune Repertoire Capture (IRC) technology generates natively paired heavy and light chain sequences of the antibodies expressed by single B cells isolated from patient samples.
You don't have any saved screeners yet
